Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Affiliations

¹ Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
² Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
³ Santa Casa de Misericordia de Santos, Santos, Brazil.
⁴ Tiziana LifeScience, Doylestown, PA, United States.
⁵ Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Published Erratum

Thais G Moreira et al. Front Immunol. 2022.

. 2022 Jan 12:12:815812.

doi: 10.3389/fimmu.2021.815812. eCollection 2021.

¹ Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
² Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
³ Santa Casa de Misericordia de Santos, Santos, Brazil.
⁴ Tiziana LifeScience, Doylestown, PA, United States.
⁵ Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2021.709861.].

Keywords: COVID-19; SARS-CoV-2; anti-CD3; foralumab; immune responses.

Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
Moreira TG, Matos KTF, De Paula GS, Santana TMM, Da Mata RG, Pansera FC, Cortina AS, Spinola MG, Baecher-Allan CM, Keppeke GD, Jacob J, Palejwala V, Chen K, Izzy S, Healey BC, Rezende RM, Dedivitis RA, Shailubhai K, Weiner HL. Moreira TG, et al. Front Immunol. 2021 Aug 12;12:709861. doi: 10.3389/fimmu.2021.709861. eCollection 2021. Front Immunol. 2021. PMID: 34475873 Free PMC article.